On Tuesday, Nordic American Tanker Ltd (NYSE:NAT)’s shares declined -4.68% to $11.40.
Nordic American Tanker Ltd (NAT) declared that its Board of Directors (the “Board”) has planned the Company`s 2015 Annual General Meeting of Shareholders (the “Meeting”), to be held on June 19, 2015 at 10:00 a.m., local time, in Hamilton, Bermuda. The Board has set a record date of April 23, 2015 for the determination of the Company`s shareholders entitled to receive notice of and to vote at the Meeting or any adjournment thereof.
Nordic American Tankers Limited, a tanker company, engages in acquiring and chartering double-hull tankers. As of December 31, 2014, it owned 24 Suezmax crude oil tankers, counting two new buildings under construction. The company was founded in 1995 and is based in Hamilton, Bermuda.
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s shares dropped -7.05% to $21.74.
Aegerion Pharmaceuticals, Inc. (AEGR) declared its financial results and business highlights for the first quarter of 2015.
Highlights
- Aegerion recorded $57.3 million in net product sales of JUXTAPID(R) (lomitapide) capsules in the first quarter of 2015, representing growth of about 112% over the first quarter of 2014, and 11% growth sequentially over the fourth quarter of 2014. 84% of JUXTAPID net product sales in the first quarter of 2015 were from prescriptions written in the United States.
- Aegerion recorded $2.1 million in net product sales of MYALEPT(R) (metreleptin for injection) in the first quarter of 2015, all of which were from prescriptions written in the United States. As of April 24, 2015, 58 generalized lipodystrophy (GL) patients were active on commercial therapy.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products comprise JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, counting low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults.
At the end of Tuesday’s trade, Rosetta Resources Inc. (NASDAQ:ROSE)‘s shares dipped -6.50% to $19.86.
Rosetta Resources Inc. (ROSE) stated adjusted net income (non-GAAP) for the first quarter 2015 was a loss of $8.6 million, or $(0.13) per diluted share, as compared to adjusted net income of $45.6 million, or $0.74 per diluted share for the same period in 2014. The decrease in adjusted net income was primarily driven by lower commodity prices. Net income for the quarter, which comprised of a non-cash impairment of $798.1 million, was a loss of $539.7 million, or $(8.42) per diluted share, as compared to net income of $35.2 million, or $0.57 per diluted share, in 2014. Adjusted EBITDA (non-GAAP) was $104.8 million in the first quarter of 2015, contrast to $163.8 million in the first quarter 2014. A summary of the adjustments made to calculate adjusted net income and adjusted EBITDA is comprised of in the attached “Non-GAAP Reconciliation Disclosure” tables.
Rosetta Resources Inc., an independent exploration and production company, acquires and develops onshore energy resources in the United States. It owns producing and non-producing oil, natural gas liquids (NGLs), and natural gas properties in proven or prospective basins that are primarily located in the Eagle Ford shale in South Texas and in the Permian Basin in West Texas.
FireEye Inc (NASDAQ:FEYE), ended its Tuesday’s trading session with -6.44% loss, and closed at $40.54.
FireEye Inc (FEYE) declared financial results for the first quarter of 2015.
First Quarter 2015 Revenue and Billings
Revenue: First quarter revenue was $125.4 million, an enhance of 69 percent from the first quarter of 2014 and above the formerly issued guidance range of $118 to $122 million. Total revenue comprised of product revenue of $40.2 million, product subscription revenue of $43.4 million, support and maintenance revenue of $19.1 million and professional services revenue of $22.7 million.
Deferred revenue: Deferred revenue totaled $378.8 million at the end of the first quarter, an enhance of $166.0 million, or 78 percent, from the end of the first quarter of 2014. Current deferred revenue was $217.2 million, an enhance of $95.8 million from the end of the first quarter of 2014 and comprised of $9.7 million in deferred product revenue and $207.5 million in deferred subscription, support and services revenue.
FireEye, Inc., together with its auxiliaries, provides cybersecurity solutions for detecting, preventing, and resolving cyber-attacks. The company offers vector-specific appliance solutions that provide threat protection from network to endpoint for inbound and outbound network traffic that may contain sensitive information.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
